No Data
Minsheng Health (301507.SZ): Obtained the Pharmaceutical registration certificate for minoxidil lotion.
On March 24, Glonghui reported that Minsheng Health (301507.SZ) announced that Hangzhou Minsheng Health Pharmaceutical Co., Ltd. recently received the "Pharmaceutical Registration Certificate" approved and issued by the National Medical Products Administration for Minoxidil Solution (Specification 1: 2% (60 milliliters: 1.2 grams), Specification 2: 5% (60 milliliters: 3.0 grams)). Minoxidil Solution is an over-the-counter dermatological medication, with the 2% specification used for the treatment of male pattern hair loss and alopecia areata. The 5% specification is for male use only, intended for the treatment of male pattern hair loss and alopecia areata. Minoxidil is a peripheral vasodilator drug, which can stimulate hair growth when used topically over a long period.
Minsheng Healthcare's Chairman Proposes Share Buyback
Minsheng Health (301507.SZ): plans to repurchase 1.3 million to -1.45 million shares of the company.
On March 20, Gelonghui reported that Minsheng Health (301507.SZ) announced its plan to repurchase company shares through centralized bidding, intended for Stock-based Incentive. The expected number of shares to be repurchased is between 1.3 million and -1.45 million shares, accounting for 0.36%-0.41% of the company's current total equity. The specific number of shares to be repurchased will depend on the actual amount completed at the end of the repurchase period. The price Range for repurchased shares will not exceed 19.80 RMB/share. Based on the upper limit of the repurchase price and the upper limit of the repurchase quantity, the total repurchase fund is expected to not exceed 28.71 million RMB. The repurchase implementation period.
Investor Optimism Abounds Hangzhou Minsheng Healthcare Co., Ltd. (SZSE:301507) But Growth Is Lacking
Minsheng Health (301507.SZ): The new Business will simultaneously develop the OTC products and health products lines.
On February 20, Gelonghui reported that in a recent investor relations activity, Minsheng Health (301507.SZ) mentioned that due to the company's later entry into the health products sector compared to OTC, it has not yet formed a sizable sales scale. However, the sales of health products maintain a high growth rate, and their proportion in the company's business revenue is gradually increasing. The company will simultaneously establish its new business in both OTC products and health products, so the product structure proportion will be dynamically adjusted according to the actual business development and market demand to ensure healthy business growth and achieve optimal allocation of company resources.
Mins Health (301507.SZ): The primary sales channel for Aluminum magnesium carbonate suspension is concentrated in offline pharmacy terminals, and it is currently in the招商 and distribution stage.
On February 20, Gelonghui reported that Minsheng Health (301507.SZ) recently indicated in its investor relations activities that Magnesium Carbonate Aluminum Suspension, as a therapeutic OTC product, has its main sales channel concentrated in offline pharmacy terminals, and is currently in the stages of recruitment and distribution. The current Orders for this product are stable, but due to outsourced production, the manufacturers face certain pressures with deliveries due to the Spring Festival holiday and production scheduling. This situation is expected to be a short-term phenomenon, and it is anticipated that the product's delivery status will improve quickly.
